Condition

Neoplasm, Residual

ClinicalTrials.gov condition label

Clinical trials3

Recruiting1

Common interventions7

Lead sponsors shown3

Clinical trials

3 shown

PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCNCT05167604 · 2021-09-30

Feasibility of the LUM Imaging System for Detection of Prostate CancerNCT03441464 · 2019-03-20

Common interventions

Adjuvants, PharmaceuticDRUG1 ALX148DRUG1 Fam-Trastuzumab Deruxtecan-NxkiDRUG1 LUM Imaging SystemCOMBINATION_PRODUCT1 TTX-MC138DRUG1 TucatinibDRUG1 ZanidatamabDRUG1

Leading sponsors

Lumicell, Inc.1 QuantumLeap Healthcare Collaborative1 Tang-Du Hospital1

Trial status mix

RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE12

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.